Want to see ELVN full AI Analyst Report?
Enliven Therapeutics (ELVN) Income Statement
Enliven Therapeutics Income Statement
Last quarter (Q2 2026), Enliven Therapeutics's total revenue was $0.00. In Q2, Enliven Therapeutics's net income was $-32.48M. See Enliven Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -263.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 119.39M | $ 104.55M | $ 83.53M | $ 38.79M | $ 24.76M | |
| Depreciation and Amortization | $ 263.00K | $ 317.00K | $ 297.00K | $ 215.00K | $ 115.00K |
| $ -103.43M | $ -88.47M | $ -71.29M | $ -37.45M | $ -24.63M | |
| $ -119.66M | $ -104.55M | $ -83.53M | $ -38.79M | $ -24.76M | |
| $ 15.96M | $ 15.76M | $ 11.95M | $ 1.13M | $ 22.00K | |
| $ -103.69M | $ -88.79M | $ -71.58M | $ -37.66M | $ -24.74M | |
| $ -103.69M | $ -89.02M | $ -71.58M | $ -37.66M | $ -24.74M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.83 | $ -1.89 | $ -2.01 | $ -6.03 | $ -3.17 |
| Diluted EPS | $ -1.83 | $ -1.89 | $ -2.01 | $ -6.03 | $ -3.17 |
| Weighted Average Shares Outstanding | 56.66M | 47.07M | 35.55M | 6.25M | 7.81M |
| Weighted Average Shares Outstanding (Diluted) | 56.66M | 47.07M | 35.55M | 6.25M | 7.82M |
Currency in USD
